Fasting improves discrimination of grade 1 and atypical or malignant meningioma in FDG-PET

Journal of Nuclear Medicine

Volumn 38, Issue 1, 1997, Pages 26-30

  Cremerius, Uwe ^a   Bares, Roland ^a   Weis, Joachim ^a   Sabri, Osama ^a   Mull, Michael ^a   Michael Schroder J ^a   Gilsbach, Joachim M ^a   Buell, Udalrich ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

fluorine 18 FDG; grading; meningioma; PET

Indexed keywords

CORTICOSTEROID; FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CELL METABOLISM; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DIET RESTRICTION; FEMALE; GLUCOSE UTILIZATION; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR CELL; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DEOXYGLUCOSE; DIAGNOSIS, DIFFERENTIAL; FASTING; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0031022853     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Black PM. Brain tumors (second of two parts). N Engl J Med 1991;324:1555-1564.
2. Maier H, Oefner D, Hittmair A, Kitz K, Budka H. Classic, atypical and anaplastic meningioma: three histopathological subtypes of clinical relevance. J Neurosurg 1992;77:616-623.
3. Di Chiro G, Hatazawa J, Katz DA, Rizzoli HV, De Michele DJ. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology 1987;164:521-526.
4. Lindholm P, Minn H, Leskinen-Kallio S, et al. Influence of blood glucose concentration on FDG uptake in cancer - a PET study. J Nucl Med 1993;34:1-6.
5. 18F]fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology 1992;183:643-647.
6. 18F-labeled deoxyglucose: method and first results. Nucl Med Commun 1993;14:596-601.
7. Hierholzer K, Schmidt RF. Pathophysiology in man. Weinheim. Germany: VCH Publishing Co.; 1991.
8. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumors. Brain Pathol 1993;3:255-268.
9. Kaiser HJ, Sabri O, Wagenknecht G, et al. A method of correlating and merging cerebral morphology and function by a special headholder. Nuklearmedizin 1994;33: 123-126.
10. Cremerius U, Striepecke E, Henn W, et al. FDG-18 PET in intracranial meningioma versus grading, proliferation index, cellular density and cytogenetical analysis. Nuklearmedizin 1994;33:144-149.
11. Henn W, Cremerius U, Heide G, et al. Monosomy 1p is correlated with enhanced in vivo glucose metabolism in meningiomas. Cancer Genet Cytogenet 1995;79:144-148.
12. 14C-deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897-916.
13. 18F]2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979;6:371-388.
14. Di Chiro G, Brooks RA. PET quantification: blessing and curse. J Nucl Med 1988;29:1603-1604.
15. Okazumi S, Isono K, Enomoto K, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 1992;33:333-339.
16. 18F]fluorodeoxyglucose PET with glucose loading. J Comput Assist Tomogr 1994; 18:12-15.
17. Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of fluorine-18-fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995;195:47-52.